Securities code: 300942 securities abbreviation: Shenzhen Bioeasy Biotechnology Co.Ltd(300942) Announcement No.: 2022-005 Shenzhen Bioeasy Biotechnology Co.Ltd(300942)
Performance forecast for 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Performance forecast of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected performance: rising in the same direction
The current reporting period of the project is the same period of last year
Profit attributable to shareholders of listed companies: 22 million yuan – 260 million yuan
Net profit: 65.4451 million yuan, an increase of 236.16% – 297.28% over the same period last year
Profit after deducting non recurring profit and loss: 198 million yuan – 238 million yuan
Net profit: 56.8778 million yuan, an increase of 248.11% – 318.44% over the same period last year
2、 Communication with accounting firms
The company has made pre communication with the annual report audit accounting firm on matters related to the performance forecast, and there is no difference between the company and the accounting firm on the performance forecast in the reporting period.
3、 Explanation of performance change reasons
1. In the first half of 2021, the global epidemic situation was repeated. Some European countries such as Germany and the United Kingdom implemented family self-test, and the demand for covid-19 antigen self-test reagent in overseas markets increased greatly; In the fourth quarter, affected by the high transmission of variant strains such as Omicron, the global epidemic prevention and control was upgraded, and the demand of overseas antigen detection market increased again. With the advantages of technology and quality control, the orders and revenue of covid-19 antigen detection reagent semi-finished products and supporting solutions of the company increased, which contributed to a significant increase in performance in 2021.
2. During the reporting period, the impact of non recurring profits and losses on the company’s net profit is expected to be about 22 million yuan, mainly due to government subsidies and financial income.
4、 Other instructions
This performance forecast is the result of the preliminary accounting of the company’s financial department. It has not been audited by an accounting firm and may be different from the final data disclosed in the annual report. The specific financial data will be disclosed in detail in the 2021 annual report. Please make careful decisions and pay attention to investment risks.
5、 Documents for future reference
1. Description of the board of directors on the performance forecast of the current period.
It is hereby announced.
Shenzhen Bioeasy Biotechnology Co.Ltd(300942) board of directors January 20, 2022
